title: Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.
abstract: BACKGROUND
  The ZoMaxx I and II trials were randomized controlled studies of the zotarolimus-eluting, phosphorylcholine-coated, TriMaxx stent for the treatment of de novo coronary lesions. The aim of this study was to compare the vessel response between zotarolimus- (ZES) and paclitaxel-eluting stents (PES) using intravascular ultrasound (IVUS).
  
  
  RESULTS
  Data were obtained from the ZoMaxx I and II trials, in which a standard IVUS parameter was available in 263 cases (baseline and 9-months follow up). Neointima-free frame ratio was calculated as the number of frames without IVUS-detectable neointima divided by the total number of frames within the stent. While an increase in vessel and plaque was observed in PES from baseline to follow up, there was no significant change in ZES. At follow up, % neointimal obstruction was significantly higher (15.4 ± 8.8% vs 11.3 ± 9.7%), and minimum lumen area at follow up was significantly smaller in ZES compared to PES. However, the incidence of IVUS-defined restenosis (maximum cross-sectional narrowing >60%) was similar in the 2 groups (3.2% vs 6.7%). Neointima-free frame ratio was significantly lower in ZES. There were 5 cases of late incomplete stent apposition in PES and none in ZES.
  
  
  CONCLUSIONS
  These IVUS results demonstrate a similar incidence of severe narrowing between these 2 DES. There was a moderate increase in neointimal hyperplasia that was associated with a greater extent of neointimal coverage in ZES compared with PES.
authors.affiliation: Stanford University, Stanford, CA, USA.
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Waseda
authors.forename: Takao
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Junya
authors.initials: J
authors.lastname: Ako
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Honda
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
authors.forename: Robert
authors.initials: R
authors.lastname: Whitbourn
authors.forename: John
authors.initials: J
authors.lastname: Ormiston
authors.forename: Charles D
authors.initials: CD
authors.lastname: O'Shaughnessy
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Henry
authors.forename: Paul
authors.initials: P
authors.lastname: Overlie
authors.forename: Lewis B
authors.initials: LB
authors.lastname: Schwartz
authors.forename: Krishnankutty
authors.initials: K
authors.lastname: Sudhir
authors.forename: Bernard
authors.initials: B
authors.lastname: Chevalier
authors.forename: William A
authors.initials: WA
authors.lastname: Gray
authors.forename: Alan C
authors.initials: AC
authors.lastname: Yeung
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Fitzgerald
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging* / Q000209:etiology; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D017239:Paclitaxel / Q000008:administration & dosage*; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000000981:diagnostic imaging; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus